NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Core Viewpoint - Nanobiotix's lead candidate NBTXR3 shows promising safety and efficacy in cancer treatment, particularly in combination with anti-PD-1 therapy, with several clinical milestones anticipated in the next 12-18 months [1][2]. Company Updates - Nanobiotix has strengthened its Supervisory Board with the addition of Dr. Margaret A. Liu and Ms. Anat Naschitz, enhancing the company's capacity for sustainable growth [3]. - The company achieved a significant operational milestone in its collaboration with Janssen Pharmaceutica NV, receiving a $20 million payment as part of their licensing agreement [4]. Clinical Trials and Milestones - NBTXR3 is being evaluated in multiple clinical trials, including a Phase 3 trial (NANORAY-312) for locally advanced head and neck squamous cell carcinoma, with interim analysis expected by 1H2026 [4]. - A Phase 2 study for non-small cell lung cancer (NSCLC) is underway, with the first patient randomized as the next milestone [5]. - Study 1100 has shown a 48% overall response rate in anti-PD-1 naïve patients and a 28% response rate in resistant patients, indicating the potential of NBTXR3 to prime immune responses [5]. Financial Performance - For the first half of 2024, revenue increased to €9.3 million from €3.3 million in the same period of 2023, primarily due to the licensing agreement with Janssen [7]. - Research and development expenses rose to €22.0 million, driven by increased clinical activities, compared to €17.8 million in the previous year [8]. - The net loss for the first half of 2024 was €21.9 million, an improvement from €28.1 million in the same period of 2023 [10]. Cash Position - As of June 30, 2024, the company reported €66.3 million in cash and cash equivalents, extending its cash runway into Q4 2025 [11].